



PEPTIDESWAP

The peptide marketplace people trust.

WORKING WHITEPAPER / VERSION 0.5 / SEPTEMBER 2026

Information.
Dealer checks.
Protected trades.
Purchase-linked reviews.



TOKEN	\$PEPS
LAUNCH	September 21, 2027
PUBLIC PRESALE	120M PEPS / \$2M target

Presale-stage working proposal. Not an offer, medical advice, or a promise of returns. Final terms require legal review, audited contracts, and public disclosure.



Built for a market becoming larger - and harder to navigate.

PeptideSwap is designed as a privacy-conscious marketplace and information layer for the peptide economy. It brings discovery, dealer identity and operating-location checks, documented order terms, escrow-based release conditions, disputes, and purchase-linked reviews into one path.

CORE PROMISE	Research the market. Know the dealer. Protect the trade.
BUSINESS ENGINE	A small fee on completed transactions supports the ecosystem.
TOKEN ROLE	\$PEPS supports the presale and future documented ecosystem programs.

The opportunity

Peptide therapeutics are already a major pharmaceutical category. Independent market estimates differ by methodology, but multiple 2026 reports project high-single-digit to low-double-digit annual growth through the next decade. Meanwhile, major manufacturers report extraordinary commercial concentration and volume growth around peptide-based metabolic products.

PeptideSwap does not assume that pharmaceutical-market growth automatically becomes marketplace revenue. The thesis is narrower: as awareness, research, product variety, manufacturing, and consumer interest expand, the value of reliable information, accountable counterparties, privacy-aware records, and protected settlement should rise with them.

What this paper does

- Defines the six-step marketplace flow and the verification boundaries.
- Documents a \$2 million, six-round public presale beginning at \$0.01.
- Publishes the proposed 500 million fixed supply, allocations, release schedules, and use of funds.
- Sets a Q3 2027 token launch date and describes the controls required before activation.



Why 2027 matters.

A category moving from specialist to mainstream

Grand View Research estimates the global peptide therapeutics market at \$140.9 billion in 2025, \$164.0 billion in 2026, and \$294.6 billion by 2033, an 8.7% compound annual growth rate. Fortune Business Insights separately estimates \$146.34 billion in 2026 and \$334.95 billion by 2034, a 10.91% CAGR. These are third-party forecasts, not PeptideSwap projections.

Signal	Published evidence	Why it matters
Market expansion	\$164.0B estimated in 2026; 8.7% CAGR to 2033	More products, participants and information to evaluate
GLP-1 demand	Novo reported 104% global branded obesity-market volume growth in 2025	Peptide awareness has moved into mainstream health conversation
Commercial scale	Mounjaro and Zepbound were 56% of Lilly 2025 revenue	Peptide-based products can anchor very large commercial categories
Regulatory depth	FDA expects more generic peptide approvals	Verification and analytical standards become more important as access expands

Our 2027 view

The evidence supports continued momentum into 2027: expanding metabolic demand, new delivery formats, generic development, manufacturing investment, and broader pipelines. It does not support a guarantee that every peptide category, supplier, or token will grow. PeptideSwap is positioned around market infrastructure - information, counterparty accountability, transaction protection, and auditable records - rather than making a directional bet on one compound.

The key distinction: a booming category creates opportunity and complexity at the same time. PeptideSwap is designed for the complexity.



Trust is the missing layer.

Discovery today can be fragmented across storefronts, private groups, search results, and unstructured claims. A buyer may struggle to distinguish a business identity check from a product test, understand who controls payment, compare dispute rules, or know whether a review reflects a completed purchase.

PROVIDE	Useful information, news, and educational context
PROTECT	Escrow-based trades with documented release conditions
VERIFY	Dealer identity and operating location, with scope and date
REVIEW	Feedback linked to completed marketplace transactions
RESPECT	Privacy controls for identity, payment, delivery, and order records

Verification has boundaries

A dealer badge must state what was checked, by whom, when, and what remains outside scope. Identity, location, laboratory documentation, and transaction history are separate evidence types. None independently establishes that a product is approved, safe, effective, authentic, or suitable for a specific use.

Privacy by design

Participants should see only the information needed for their role. Public profiles can show verification status and dates without exposing private order data. The final architecture must define retention, access, deletion, dispute evidence, lawful requests, and the custody responsibilities of every service provider.



From search to settlement.

Step	What happens	Record created
01 Search	Browse eligible listings by category, location, fulfillment area, and attached records.	Comparable listing profile
02 Inspect	Review dealer checks, marketplace history, policies, and latest record dates.	Time-stamped dealer profile
03 Agree	Set item, batch reference where applicable, quantity, price, shipping, acceptance, and dispute terms.	Versioned order agreement
04 Fund	Place payment into the disclosed escrow flow under published release conditions.	Auditable escrow timeline
05 Resolve	Attach shipment, receipt, confirmation, and dispute evidence to one shared record.	Transaction evidence record
06 Release	Release under agreed conditions and enable feedback tied to the completed trade.	Settlement receipt and review

Escrow is a process, not a magic shield.

The final escrow provider, custody model, fees, eligible jurisdictions, release triggers, evidence standards, response periods, decision authority, appeal process, and emergency controls must be disclosed before marketplace activation.

The marketplace can be built during the presale while the public pitch describes the intended finished experience. Capability claims must remain aligned with what is actually available at each phase.



\$PEPS: fixed supply, public math.

MAXIMUM SUPPLY	500,000,000 PEPS
PUBLIC PRESALE	120,000,000 PEPS / 24%
TARGET RAISE	\$2,000,000
TRANSFER TAX	0% proposed

Six-round public presale

The PeptideSwap ladder uses six progressively priced rounds. Smaller opening and closing allocations create clear milestones, while the larger middle rounds provide most of the fundraising capacity. Full subscription raises exactly \$2 million while PEPS begins at \$0.01.

Round	Price	PEPS available	Round raise	Increase
1	\$0.0100	6,000,000	\$60,000	-
2	\$0.01333	9,000,000	\$120,000	33.3%
3	\$0.0150	21,000,000	\$315,000	12.5%
4	\$0.01667	36,000,000	\$600,000	11.1%
5	\$0.01833	33,000,000	\$605,000	10.0%
6	\$0.0200	15,000,000	\$300,000	9.1%
Total	\$0.016667 avg	120,000,000	\$2,000,000	-

Early participation: \$1,000 buys 100,000 PEPS in Round 1 and 50,000 PEPS in Round 6. This is a token-quantity difference, not a promised return.

Buyer claim process: Purchases record allocations on-chain; PEPS is not delivered during the presale. After the sale closes and before claims open, the treasury transfers enough PEPS to cover every recorded buyer allocation. At token generation, buyers manually claim the first 20%. The remaining 80% unlocks continuously over 180 days and is collected through later manual claims. Each claim requires a network transaction.

Public verification: The contract exposes outstanding buyer liabilities and any funding shortfall. Unclaimed PEPS remains reserved for buyers. Failure to fund the contract before claims open would prevent claims and is a material execution risk.

Editable, but buyer-safe: Before the first purchase, vesting can be enabled, disabled, or revised. Once purchases exist, multisignature governance may only increase the initial unlock, shorten vesting, or remove vesting entirely so 100% is claimable at TGE. Removed vesting cannot then be restored for existing buyers.

ETH, USDC, USDT and future cards: Each enabled ERC-20 uses its actual decimals and its own validated USD feed. Future Wert checkout can buy ETH and call the payable `buyWithEthFor` function with the buyer as beneficiary. Wert requires a verified contract, encoded call data, merchant approval, and a server-generated request signature.



Where the supply goes.

Allocation	Share	Tokens	Working release
Public presale	24%	120M	20% TGE; 80% daily / 180 days
DAO research and stewardship	22%	110M	DAO multisig; approved votes only
Team	15%	75M	Monthly / 36 months
Ecosystem adoption	10%	50M	Monthly / 48 months
Product treasury	10%	50M	Monthly / 48 months; multisig
DEX liquidity	6%	30M	Opening liquidity + reserve
CEX liquidity	8%	40M	Confirmed listings only
Strategic partners	5%	25M	Monthly / 24 months

DAO purpose: independently reviewed research summaries, source verification, education, marketplace moderation, dispute participation, governance, security bounties, and approved public goods. Rewards require published work or milestones. The CEX reserve moves only after a named listing or disclosed market-maker agreement.

Use of a fully subscribed \$2 million raise

Use	Share	Amount
Marketplace product and security	30%	\$600,000
DEX liquidity	25%	\$500,000
Legal and compliance	20%	\$400,000
Marketing and community growth	15%	\$300,000
Marketplace operations	10%	\$200,000

At an illustrative \$0.025 opening-pool ratio, \$500,000 pairs with 20 million PEPS and creates \$1 million in two-sided pool value. The ratio is 25% above the final presale round and implies a \$12.5 million FDV. It is not a guaranteed market price or price floor.



07 / ECOSYSTEM MODEL

A marketplace that funds its next step.

Presale proceeds finance the initial build. A future fee on completed transactions is proposed to support continuing development.

50%	Token-mechanism reserve
50%	Ecosystem treasury

The token-mechanism half may fund locking, burning, or buyback-and-burn only if legal, technical, and economic review supports it. The treasury half supports product, security, compliance, operations, news, and education. The final fee rate, routing, execution method, reporting schedule, and governance must be public and auditable.

Road to Q3 2027

Phase	Delivery focus
01 Foundation	Finalize sale terms; publish contracts; establish treasury controls.
02 Protocol	Dealer profiles; verification records; listings; escrow workflow; purchase-linked reviews.
03 Controlled beta	Limited eligible participants; dispute handling; security and operational testing.
04 Expansion	Eligible dealer growth; more education and news; approved ecosystem programs.
Token launch	September 21, 2027 at 10:00 AM ET / 14:00 UTC.

Marketplace milestone timing remains subject to regulatory, technical, security, and operational readiness. Any change to the token launch date must be announced consistently across official channels.



Trust must be operational.

Required before activation

- Final legal entity, eligible jurisdictions, purchaser requirements, offering terms, minimum raise, refunds, deadlines, and unsold-token treatment.
- Independent audits of the token, sale, vesting, treasury, escrow, and fee-routing contracts.
- Public allocation wallets, vesting contracts, treasury signers, multi-signature controls, and access policies.
- Published circulating supply, upcoming unlocks, liquidity venue, pool structure, and project LP commitment.
- Dealer standards, prohibited-product rules, privacy architecture, dispute procedures, and appeal mechanisms.

Principal risks

PEPS may lose some or all of its value. Presale and scheduled token releases create selling capacity. Liquidity may be limited and prices volatile. Smart contracts, wallets, custody providers, payment services, and counterparties can fail. Laws and enforcement priorities can change. Marketplace development may be delayed or unsuccessful.

Verification and escrow reduce certain process risks but cannot eliminate fraud, product, medical, legal, custody, delivery, or market risk. \$PEPS does not represent equity and does not guarantee revenue rights, price appreciation, liquidity, yield, or delivery of a marketplace milestone.

Status

This is a working paper for community and professional review. Terms may change before a sale opens. Any revision must be reflected consistently across the website, contracts, sale interface, and final legal documentation.



Sources and definitions.

Grand View Research, Peptide Therapeutics Market (2026)

<https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market>

Market estimates: \$140.9B in 2025, \$164.0B in 2026, \$294.6B by 2033, 8.7% CAGR.

Fortune Business Insights, Peptide Therapeutics Market (2026)

<https://www.fortunebusinessinsights.com/industry-reports/peptide-therapeutics-market-101420>

Independent forecast: \$146.34B in 2026 to \$334.95B by 2034, 10.91% CAGR.

Novo Nordisk Annual Report 2025

<https://annualreport.novonordisk.com/2025/>

Reported 104% volume growth in the global branded GLP-1 obesity market.

Eli Lilly 2025 Form 10-K

<https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm>

Reported Mounjaro and Zepbound as 56% of 2025 company revenue.

FDA FY 2025 GDUFA Performance Report

<https://www.fda.gov/media/191187/download>

Discusses peptide characterization and the first generic once-daily GLP-1 approval.

Definitions

PEPS: proposed PeptideSwap ecosystem token. TGE: token generation event. Escrow: a disclosed process in which payment is held until release conditions are satisfied. Verification: a scoped check whose source, date, and limitations must be shown. FDV: token price multiplied by maximum supply; it is not the same as circulating market capitalization.

Official PeptideSwap channels

[Website](#) / [X](#) / [Telegram](#) / [Instagram](#) / [Facebook](#) / [YouTube](#) / [Reddit](#) / [TikTok](#)

Only channels linked from peptideswap.com should be treated as official. Never share a wallet seed phrase or private key.

PeptideSwap / Peptide marketplace. People trust.